No Data
No Data
Kyorin Pharmaceutical: Confirmation letter
Kyorin Pharmaceutical: Interim Report - 67th term (2024/04/01 - 2025/03/31)
SASMED - 1Q sales slightly decreased, revenue from DTx platform business remains stable.
On the 8th, Sasmeldo <4263> announced its first quarter financial results for the June 2025 fiscal year (July-September 24). Operating income decreased by 1.4% year-on-year to 0.032 billion yen, operating loss was 0.161 billion yen (compared to a loss of 0.15 billion yen in the same period last year), ordinary loss was 0.163 billion yen (compared to a loss of 0.145 billion yen last year), and quarterly net loss was 0.163 billion yen (compared to a loss of 0.146 billion yen last year). There was no recognition of operating income for the DTx product business (same as the same period last year), and segment loss was 0.04 billion yen (compared to last year).
Nissan revised its operating profit downwards to 150 billion yen from 500 billion yen on March 25th.
Nissan <7201> announced a revision to its 2025 fiscal year financial estimates. The operating profit was revised downward from 500 billion yen to 150 billion yen. The assumed exchange rate was revised to 1 dollar = 149 yen (previously 1 dollar = 155 yen), and 1 euro = 164 yen (previously 1 euro = 167 yen). The global passengers carried is set at 3.4 million units, down from the previous estimate of 3.65 million units. It was also announced that they will sell some of the shareholding in Mitsubishi Motors <7211>. [Positive Assessment] <5801> Furukawa Electric midterm | <674
Kyorin Pharmaceutical: Notice regarding differences between consolidated earnings forecasts and actual results for the second quarter (interim period) of the fiscal year ending March 31, 2025
Kyorin Pharmaceutical: Supplementary financial information for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025
No Data
No Data